AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23379651
Drug: rFSH with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFSH with metformin
Trial: 17933162
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg x kg(‐1) caudal morphine
Trial: 17933162
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg x kg(‐1) caudal morphine
Trial: 17933162
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg x kg(‐1) caudal morphine
Trial: 10740331
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg piperazine oestrone sulphate + 0.7 mg norethisterone (highEP)
Trial: 10740331
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg piperazine oestrone sulphate + 0.35 mg norethisterone (lowEP)
Trial: 10740331
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17 beta‐oestradiol continuously combined with 1 mg norethisterone acetate (E2+NETA)
Trial: 10740331
Drug: All hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All hormone groups (highEP, lowEP, E2+NETA)
Trial: 8472696
Drug: Carbohydrate drink
RxNorm normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate drink (5.0 ml.kg‐1 body weight of a 19.7% carbohydrate drink)
Trial: 30970442
Drug: PPI plus
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI plus alginate (combination)
Trial: 26377199
Drug: Iron-fortified complementary
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified complementary food (CF-FeFum) with 2 mg iron as NaFeEDTA and 3.8 mg iron as ferrous fumarate 6 days per week (n=126)
Trial: 26377199
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of porridge, an iron-fortified CF with the composition currently on the Ivorian market (CF-FePP) providing 2 mg iron as NaFeEDTA and 3.8 mg iron as ferric pyrophosphate 6 days per week (n=127)
Trial: 11418354
Drug: Escalating interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating interferon dose (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months; escalated to 9 MU at 6 weeks if HCV RNA detectable at 4 weeks)
Trial: 11418354
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (6 MU alpha-2a thrice weekly for 3 months, then 3 MU thrice weekly for 3 months)
Trial: 9545672
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) 10.0 mg/kg
Trial: 9545672
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) 21.4 mg/kg
Trial: 9545672
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) 40.0 mg/kg
Trial: 8393638
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 1 mg twice per day (n = 7)
Trial: 3540504
Drug: Clonidine (CLO)
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine (CLO) 0.36 mg daily
Trial: 3540504
Drug: Propranolol (PRO)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PRO) 160 mg daily
Trial: 3540504
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 70 mg daily
Trial: 26711179
Drug: High-dose ergocalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ergocalciferol (vitamin D2)
Trial: 21852389
Drug: Epley maneuver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epley maneuver + 24 mg betahistine 2 times daily for 1 week
Trial: 21852389
Drug: Epley maneuver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epley maneuver + placebo 2 times daily for 1 week
Trial: 14551301
Drug: Intranodal (IN)
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranodal (IN) administration of peptide-pulsed DC vaccines
Trial: 14551301
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) administration of peptide-pulsed DC vaccines
Trial: 14551301
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of peptide-pulsed DC vaccines
Trial: 1813067
Drug: Cytosol protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytosol protein content (4.15 mg/ml cut-off)
Trial: 6337769
Drug: Triamterene (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (200 mg)
Trial: 6337769
Drug: Frusemide (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide (80 mg daily) with indomethacin (150 mg daily)
Trial: 6337769
Drug: Spironolactone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (300 mg) with indomethacin (150 mg daily)
Trial: 6337769
Drug: Hydrochlorothiazide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (100 mg) with indomethacin (150 mg daily)
Trial: 6337769
Drug: Triamterene (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene (200 mg) with indomethacin (150 mg daily)
Trial: 31943506
Drug: 3-month fluoropyrimidine-oxaliplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Trial: 31943506
Drug: 6-month fluoropyrimidine-oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-month fluoropyrimidine-oxaliplatin adjuvant chemotherapy
Trial: 14720527
Drug: Admission troponin
RxNorm normalized name: atropine sulfate Ophthalmic Solution [Ocu-tropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission troponin T (tnT) >/=0.1 microg/l (n=116)
Trial: 14720527
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tnT elevation and no ST-segment resolution
Trial: 8295050
Drug: Morphine (MS)
RxNorm normalized name: morphine Extended Release Oral Tablet [MS Contin]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (MS)
Trial: 24461903
Drug: Losmapimod 15
RxNorm normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 15 mg
Trial: 24461903
Drug: Losmapimod 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 7.5 mg
Trial: 24461903
Drug: Losmapimod 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 2.5 mg
Trial: 26033641
Drug: Losmapimod 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod 7.5 mg and 15 mg
Trial: 16079172
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (etanercept 25 mg twice weekly + methotrexate up to 20 mg weekly)
Trial: 16079172
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) up to 20 mg weekly
Trial: 16079172
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy and etanercept
Trial: 12545341
Drug: basiliximab 1
RxNorm normalized name: basiliximab 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basiliximab 1 x 40-mg group
Trial: 12545341
Drug: basiliximab 2
RxNorm normalized name: basiliximab 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basiliximab 2 x 20-mg group
Trial: 10924561
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (180 mL of iopromide containing 370 mg of iodine per milliliter)
Trial: 10924561
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (180 mL of iopromide containing 300 mg of iodine per milliliter)
Trial: 8831332
Drug: Clonidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (2 micrograms/kg bolus followed by infusion at 2 micrograms.kg-1.h-1)
Trial: 8831332
Drug: Clonidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (4 micrograms/kg bolus followed by infusion at 4 micrograms.kg-1.h-1)
Trial: 3973383
Drug: 6 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 micrograms HA of trivalent surface-antigen influenza virus vaccine
Trial: 3678549
Drug: Tenoxicam (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (oral and intradermal administration)
Trial: 3678549
Drug: Tenoxicam, piroxicam,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam, piroxicam, and benoxaprofen (10-40 micrograms/ml) in vitro
Trial: 25813447
Drug: Pazopanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (800 mg once daily) for 8 to 16 weeks
Trial: 23649780
Drug: Shock absorption
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock absorption (both groups)
Trial: 11025394
Drug: Phyto Hypophyson
RxNorm normalized name: phytol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyto Hypophyson L
Trial: 8979740
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no amiodarone therapy)
Trial: 1632533
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg IV)
Trial: 6152615
Drug: Common emulsion
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common emulsion antacid
Trial: 30794574
Drug: Overall readability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall readability and comprehensibility of medication labels
Trial: 25171074
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel 2%
Trial: 25171074
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel 3.5%
Trial: 25171074
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel 5%
Trial: 25171074
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel 8%
Trial: 25171074
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel 12%
Trial: 20616293
Drug: Family medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family medicine setting (n = 116)
Trial: 18199105
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg
Trial: 17765245
Drug: Gliclazone 80
RxNorm normalized name: gliclazide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazone 80 mg
Trial: 19496272
Drug: Fluvastatin 40
RxNorm normalized name: fluvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg twice daily, commencing at least 2 weeks before planned PICA
Trial: 2668397
Drug: Thymomodulin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymomodulin (120 mg/day)
Trial: 326332
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection of triamcinolone
Trial: 22142020
Drug: Caffeine 3
RxNorm normalized name: caffeine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3 mg x kg(‐1) body mass
Trial: 22142020
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg x kg(‐1) body mass
Trial: 15237003
Drug: Soy phytoestrogens
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy phytoestrogens (150 mg of isoflavones per day) for 5 years
Trial: 15237003
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 5 years
Trial: 12564661
Drug: Structured care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured care with atorvastatin 10-80 mg
Trial: 12564661
Drug: Structured care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured care with atorvastatin 10-20 mg
Trial: 9173270
Drug: Accelerated thrombolytic
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated thrombolytic therapy with recombinant tissue plasminogen activator (t-PA)
Trial: 9173270
Drug: Primary coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary coronary angioplasty with heparin
Trial: 3588512
Drug: Disopyramide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide administered as a bolus injection of 150 mg over 5 min.
Trial: 3588512
Drug: Disopyramide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide administered as a bolus injection of 150 mg over 20 min.
Trial: 3588512
Drug: Disopyramide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide administered over 5 min.
Trial: 3588512
Drug: Disopyramide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide administered over 20 min.
Trial: 12660530
Drug: Indinavir/ritonavir (IDV/RTV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir/ritonavir (IDV/RTV) 800 mg/100 mg q12h
Trial: 12660530
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indinavir (IDV) 800 mg q8h
Trial: 11908356
Drug: New formulation
RxNorm normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulation dentifrice containing 5.0% potassium nitrate and 0.454% stannous fluoride in a silica base
Trial: 11908356
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available nondesensitizing control dentifrice (Colgate Winterfresh Gel)
Trial: 7877829
Drug: Fat Mobilisation
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat Mobilisation System (FMS) - bandaging with elasticated bandages soaked in active solution able to lower body temperature by 2-3 degrees C
Trial: 29655779
Drug: VERSAFIBE™ 2470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VERSAFIBE™ 2470 resistant starch muffin top (11.6 g TDF)
Trial: 29655779
Drug: Control muffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control muffin top (0.9 g TDF)
Trial: 28932087
Drug: 13C‐urea breath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13C‐urea breath test (UBT) with new test meal after 29 days of esomeprazole 40 mg
Trial: 24576686
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (within normal physiologic range)
Trial: 24576686
Drug: Gonadotropin releasing
RxNorm normalized name: Gonadotropin releasing factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin releasing hormone antagonist
Trial: 17414590
Drug: metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin + low-dose glimepiride + ADA diet + physical activity
Trial: 17414590
Drug: metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin + ADA diet + physical activity
Trial: 17414590
Drug: ADA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA diet + physical activity (no drugs)
Trial: 11902986
Drug: terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine (250 mg/d for 12 or 16 weeks)
Trial: 11902986
Drug: itraconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: itraconazole (400 mg/d for 1 week in every 4 for 12 or 16 weeks)
Trial: 11902986
Drug: subsequent terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subsequent terbinafine treatment
Trial: 8291967
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Stimulation (FES) therapy for shoulder muscles (supraspinatus and posterior deltoid), up to 6 hours a day for 6 weeks
Trial: 29429459
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii powder combined with azithromycin sequential therapy
Trial: 29429459
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment combined with azithromycin sequential therapy
Trial: 26164587
Drug: 100% O(2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% O(2) administration
Trial: 26164587
Drug: Sham O(2)
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham O(2) administration
Trial: 22985547
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy guide
Trial: 21575939
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg misoprostol inserted into the posterior vaginal fornix 3 hours before OH
Trial: 21575939
Drug: Vaginal examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal examination without misoprostol administration (control)
Trial: 17506119
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate (600 microg Cr(+3)) with biotin (2 mg)
Trial: 9186096
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.5 mg/ml for 3 1/2 minutes)
Trial: 9186096
Drug: 5-fluorouracil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (50 mg/ml for 5 minutes)
Trial: 1357551
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (500 micrograms)
Trial: 1357551
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (500 micrograms) after 7 days
Trial: 17989308
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart CSII
Trial: 17989308
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro CSII
Trial: 15667599
Drug: Caffeine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (100 mg) inhalation
Trial: 15667599
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of caffeine
Trial: 10613642
Drug: Natural streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural streptokinase (nSK) 1.5 million units, one-hour intravenous infusion
Trial: 10613642
Drug: Recombinant streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant streptokinase (rSK) 1.5 million units, one-hour intravenous infusion
Trial: 7844604
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion fluorouracil (5FU) 200 mg/m2/d via a Hick‐man line for 6 months with epirubicin 50 mg/m2 IV and cisplatin 60 mg/m2 IV every 3 weeks for eight courses
Trial: 7844604
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (control group)
Trial: 1742815
Drug: 0.25 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg.kg‐1 ketamine iv
Trial: 1742815
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 ketamine iv